Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2022-06-28 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Half-year Report
Interim / Quarterly Report Classification · 95% confidence The document is an 'Interim Results' announcement for Oxford BioDynamics PLC for the six-month period ended 31 March 2022. It contains financial highlights (revenue, operating loss, cash position), operational updates, and a Chief Executive Officer's review. While it is an announcement of results, it provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR) rather than a mere publication announcement (RPA). H1 2022
2022-06-28 English
EpiSwitch® CiRT now available in the UK
Regulatory Filings Classification · 98% confidence The document starts with an 'RNS Number' and a date, indicating a regulatory or news service filing. The content is an announcement from Oxford BioDynamics Plc regarding the availability of their Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) in the UK. It details the test's performance metrics, market context, and includes quotes from management and external experts. Crucially, the end of the document states: 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' and 'Reach announcements are identified with an orange label...'. This structure strongly suggests a general press release or news announcement distributed via the RNS platform, rather than a specific statutory financial filing like a 10-K, IR, or ER. Since it is a general announcement that doesn't fit the specific categories (like DIV, CAP, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous announcements distributed through regulatory channels that are not specific financial reports.
2022-06-21 English
Notice of Interim Results Webinar
Earnings Release Classification · 99% confidence The document is a regulatory announcement filed via RNS (RNS Number: 2334P) on June 17, 2022. The core content announces that the management team will conduct a live presentation (webinar) for investors following the release of their 'interim results for the half-year ended 31 March 2022' on June 28, 2022. This document is not the interim report itself (which would be an IR filing), nor is it the earnings release (ER) which typically contains the results summary. Instead, it is an announcement about the upcoming publication/discussion of those results. Since it is an announcement regarding the publication of a report (Interim Results), it fits best under Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for this context. H1 2022
2022-06-17 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (5172 characters) released via RNS (London Stock Exchange news service). The title is "Notice of Interim Results". The text explicitly states that the company "expects to announce its interim results for the half-year ended 31 March 2022 on 28 June 2022." This is not the actual Interim Report (IR) itself, but an announcement about when the report will be released. According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2022-06-15 English
OBD EpiSwitch® CiRT well received at ASCO 2022
Regulatory Filings Classification · 95% confidence The document is identified by the RNS Number header and contains a date (14 June 2022), indicating a regulatory or news announcement. The content details the positive reception of Oxford BioDynamics' EpiSwitch® CiRT test at the ASCO 2022 conference, including clinical data, market interest, and CEO commentary. It is a press release format announcing business and scientific progress, not a formal financial report like a 10-K or IR. The footer explicitly states, "This information is provided by Reach, the non-regulatory press release distribution service of RNS... Reach announcements are identified with an orange label... so that they are distinguished from the RNS UK regulatory service." Since it is a non-regulatory press release announcing company news (product reception, data presentation), it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for general announcements that aren't specifically financial reports, management changes, or dividend notices. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Audit Report (AR). Given the context of being distributed via the RNS system but explicitly marked as non-regulatory press release content, RNS is the most appropriate general classification.
2022-06-14 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an RNS announcement (indicated by 'RNS Number : 3208M' and the closing boilerplate referencing RNS/LSE). The content explicitly details a 'PDMR Dealing' where Matthew Wakefield, the Non-Executive Chairman, purchased shares. This type of transaction report, detailing personal share dealings by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the specific nature of the content makes DIRS a much more precise classification than the general RNS fallback.
2022-05-20 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.